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ABSTRACT 
 
Objective: Hearing loss is a common symptom in patients with cochleovestibular schwannoma 
(VS). Clinical and histological observations have suggested that the hearing loss may be caused 
by both retrocochlear and cochlear mechanisms. Our goal was to perform a detailed assessment 
of cochlear pathology in patients with VS. 
Study Design: Retrospective analysis of temporal bone histopathology. 
Setting: Multi-center study. 
Material: Temporal bones from 32 patients with unilateral, sporadic VS within the internal 
auditory canal. 
Main Outcome Measures: Sections through the cochleae on the VS side and opposite (control) 
ear were evaluated for loss of inner and outer hair cells, atrophy of the stria vascularis, loss of 
cochlear neurons, and for presence of endolymphatic hydrops and precipitate within endolymph 
or perilymph. Observed pathologies were correlated to nerve of origin, VS volume, and distance 
of VS from the cochlea. Hearing thresholds were also assessed. 
Results: VS caused significantly more inner and outer hair cell loss, cochlear neuronal loss, 
precipitate in endolymph and perilymph, and decreased pure tone average, when compared to the 
opposite ear. Tumor size, distance from the cochlea, and nerve of origin did not correlate with 
structural changes in the cochlea or the hearing threshold. 
Conclusions: There is significant degeneration of cochlear structures in ears with VS. Cochlear 
dysfunction may be an important contributor to the hearing loss caused by VS, and can explain 
certain clinically observed phenomena in patients with VS.  
 
Key words: cochlear changes, hair cell loss, hearing loss, temporal bone histopathology, 
vestibular schwannoma 
 
Running title: Cochlear dysfunction due to cochleovestibular schwannoma
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INTRODUCTION 
 Sensorineural hearing loss (SNHL) is a common symptom caused by a schwannoma of the 
eighth nerve (acoustic neuroma, vestibular schwannoma [VS]) (1-3). In theory, the hearing loss 
may occur as a result of dysfunction of the cochlear nerve (a retrocochlear mechanism), or due to 
dysfunction of the cochlea (a cochlear mechanism), or both mechanisms may occur in a given 
case.  Clinicians commonly think of VS-associated hearing loss as occurring due to dysfunction 
of the cochlear nerve; supporting evidence includes retrocochlear abnormalities on auditory 
brainstem response measurements (4,5) and histopathologic data demonstrating atrophy of the 
cochlear nerve (6,7).  Less attention has focused on dysfunction of the cochlea caused by VS as a 
factor that contributes to the hearing loss.  Evidence that such cochlear dysfunction can occur 
comes from clinical data showing abnormalities in otoacoustic emissions in VS (8-11), and 
histopathologic data in patients with VS showing pathological changes within the cochlea such 
as degeneration of the organ of Corti and the stria vascularis, occurrence of endolymphatic 
hydrops and an acidophilic-staining precipitate within inner ear fluid spaces.  Such pathological 
changes have been reported by multiple authors in small case series ranging from 1 to 11 cases 
(12-17); in addition, Eckermeier et al. (6) described acidophilic-staining precipitate in a series of 
21 sporadic VS cases.  
 Clinical considerations would also suggest that dysfunction of the cochlea might be 
common in patients who have hearing loss due to a VS.  It has been well established that atrophy 
of the cochlear nerve (loss of cochlear neurons) disproportionately affects speech discrimination 
ability rather than pure tone hearing thresholds (18-20).  Studies have shown that over 80% of 
cochlear neurons have to be lost before there is a significant shift in pure tone thresholds, and 
that such severe neuronal losses are associated with a severe drop in speech discrimination 
ability (21,22).  Clinical data has demonstrated the occurrence of mild to moderate degrees of 
threshold shift with relatively preserved speech discrimination in patients with a VS: analysis of 
data pooled from 5 published studies (23-27) showed that a speech discrimination score (SDS) of 
> 65% was found in all patients (100%) with a preoperative pure tone average (PTA) between 20 
– 40 dB HL, in 68% of the patients with a PTA between 40 – 60 dB HL, and in 50% with a PTA 
between 60 – 80 dB HL.  Clinical studies have also shown that hearing loss does not correlate 
with the size of VS (28,29), indicating that compression of the cochlear nerve within the internal 
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auditory canal may not be the only mechanism in hearing loss. In other words, it may be that the 
commonly observed hearing losses for pure tones (in the absence of poor speech scores) in 
patients with VS may be caused by cochlear mechanisms rather than retrocochlear dysfunction.  
If true, it is possible that cochlear dysfunction is more common in VS than is perceived in 
clinical practice.  
 The goal of our temporal bone histopathologic study was to assess the occurrence of 
cochlear pathology in a relatively large series of patients with VS, by combining cases contained 
with the temporal bone collections at the Massachusetts Eye and Ear Infirmary (MEEI), House 
Ear Institute (HEI) in Los Angeles, University of Minnesota at Minneapolis (UM) and University 
Hospital of Zurich (USZ).  Our findings and results have implications for the diagnosis and 
management of VS.  
 
MATERIAL AND METHODS 
 The archives of the temporal bone collections at MEEI, HEI, UM and USZ were searched to 
meet our inclusion criteria of unilateral, untreated VS.  Both symptomatic (auditory or vestibular 
complaints) and occult cases of VS were included.  Patients with tumors due to 
neurofibromatosis type 2 were excluded.  The temporal bones had been processed for light 
microscopy using the standard method of fixation in formalin, decalcification in trichloracetic 
acid or ethylenediaminetetracetate, embedding in celloidin, serial sectioning in the axial plane at 
a thickness of 20 microns, and staining of every tenth section using hematoxylin and eosin (30).  
The respective institutional review boards approved the study.   
 Sections through the cochleae on the VS side and opposite (control) ear were evaluated for 
loss of inner and outer hair cells, atrophy of the stria vascularis and loss of cochlear neurons.  
Visual estimates were noted for the severity of degeneration for each of these structures. The 
severity of degeneration for each of these structures was evaluated in a semi quantitative manner 
utilizing rating scales have been used by us and by others for similar assessments (17, 30).  
Degeneration of inner hair cells was noted as being none (no loss in all turns), mild (less than 
one-third missing), moderate (one-third to two-thirds missing) and severe (more than two-thirds 
missing).  A similar scale was used for assessment of outer hair cells.  The degree of atrophy of 
the stria vascularis was noted in terms of percentage loss averaged throughout the cochlea and 
was characterized as none (intact stria in all three turns), mild degeneration (less than 33% 
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atrophy), moderate degeneration (34% to 66% atrophy) and severe degeneration (greater than 
67% atrophy).  Cell bodies of cochlear neurons in Rosenthal’s canal were compared to normal 
counts at birth, and degree of atrophy of neurons was characterized as none (no loss), mild 
degeneration (less than one-third missing compared to neonatal normal), moderate degeneration 
(one-third to two-thirds missing) and severe degeneration (greater than two-thirds missing).  In 
each bone, the presence of hydrops was assessed by noting the position of Reissner’s membrane 
in the cochlea, and position of the labyrinthine membranes in the vestibular end organs.  
Convexity of Reissner’s membrane toward the scala vestibuli was indicative of hydrops in the 
cochlea.  Similarly, distension of the membranous walls of the saccule, utricle or ampullae 
(compared to normal) was indicative of vestibular hydrops.  Finally, the presence or absence of 
precipitate within the endolymphatic and perilymphatic spaces was assessed. 
 The nerve of origin of the tumor (vestibular nerve, superior division of vestibular nerve, 
inferior division of vestibular nerve, or cochlear nerve) was noted in each case.  The maximum 
extent of each tumor in the horizontal plane (x and y dimensions) was measured.  Similarly, the 
height (z dimension) was calculated from the number of vertical sections containing tumor.  
Tumor volume was then calculated from the x, y and z dimensions, assuming the VS to be an 
ellipsoid.  In addition, the nearest distance of each tumor from the base of the modiolus was 
measured.  Where available, air and bone conduction thresholds and speech discrimination 
scores were noted from the last audiogram before death.  Statistical analyses were performed 
using Student’s t test, chi-squared test and regression analyses; p < 0.05 was considered as 
significant.   
 
RESULTS 
 Our initial search of the temporal bone archives captured 49 patients with 50 sporadic, 
untreated tumors (17-MEEI, 15-HEI, 11-UM and 6-USZ).  Assessment of cochlear pathology 
was not possible in 9 patients because of severe postmortem artifact, or confounding pathology 
such as postmeningitic ossification of the cochlea, cochlear implantation or congenital deafness.  
Seven tumors that were located within the cochlea or the vestibular labyrinth (intralabyrinthine 
schwannomas) were excluded.  One patient had two tumors in the same ear, one within the 
internal auditory canal and one in the cochlea; this patient was excluded because it was unclear 
which tumor had caused the observed cochlear pathology.  The final analysis consisted of a 
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detailed examination of 32 schwannomas within the internal auditory canal from 32 patients (18 
male, 14 female) with a mean age of 72 years (range 25-100 years). 
 
Assessment of Cochlear Pathology 
 Table 1 shows details of cochlear pathology for each of the 32 patients. The data shown in 
Table 1 clearly indicate that the vast majority of patients with VS showed cochlear pathology 
including degeneration of inner hair cells (75%), outer hair cells (88%), stria vascularis (69%), or 
cochlear neurons (85%). Forty three percent showed a precipitate in the endolymphatic or 
perilymphatic spaces.  Endolymphatic hydrops was seen in 25% (7 cases).  The hydrops involved 
the cochlea in all 7 cases; the saccule was also distended in 4 of the 7 cases.  
 The contralateral ear was available for assessment in 22 out of the 32 cases, thus serving as 
a control.  The severity of the cochlear pathology on the tumor side compared to the opposite ear 
in these 22 patients is shown in Table 2.  The tumor side had significantly more inner hair cell 
loss (p=0.003), outer hair cell loss (p=0.0004), and cochlear neuronal loss (p=0.002) (t test).  
There was a trend toward greater severity of strial atrophy on the tumor side, although it did not 
reach the level of significance (p=0.07) (t test).  Patients with tumors had significantly more 
precipitate in the endolymph (p=0.0001) and perilymph (p=0.0002) (chi-square analysis).  There 
was also a trend for occurrence of endolymphatic hydrops on the tumor side, but it did not reach 
statistical significance (p=0.06) (chi-square test).  Figures 1-3 show examples of VS in two 
patients, showing the occurrence of cochlear degeneration on the tumor side compared to the 
contralateral side. 
 Of the 22 patients with both ears available, 8 (36%) had occult tumors, 11 (15%) had 
symptomatic tumors, while the existence of symptoms was indeterminate in 3 (14%) patients 
because an accurate history was not available.  Symptomatic patients showed significantly more 
inner hair cells loss (p=0.03), outer hair cell loss (p=0.01), and cochlear neuronal loss (p=0.01), 
but not more strial atrophy (p=0.19) (t test).  Symptomatic ears also showed significantly more 
hydrops (p=0.002) and significantly more precipitate in the endolymph (p=0.0001) and 
perilymph (p=0.007) (chi-square analysis).  Patients with occult neoplasms did not reveal 
significant differences for any of the cochlear structures between the two sides.   
 
Correlation of Cochlear Pathology with Tumor Morphology 
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 We also performed analyses to determine if the observed cochlear pathology was correlated 
with morphologic aspects of the tumor such as its volume, distance from the cochlea and nerve 
of origin. 
 Tumor volume:  Mean tumor volume was 76 mm3 (range, 0.06 - 502.65 mm3).  No 
significant correlations were observed between tumor volume and degree of cochlear 
degeneration for all 32 cases, except for precipitate in the endolymph, which was more common 
in large tumors (p=0.045).  A t test comparing tumor volume across different categories for 
degeneration of inner hair cells, outer hair cells, strial atrophy, neuronal loss, presence of 
hydrops and precipitate found only one significant difference: large tumors showed significant 
inner ear hair cell loss (p=0.009). 
 Distance of tumor from cochlea: The nearest distance from each tumor to the modiolus was 
measured and compared to degeneration within the cochlear structures.  The mean distance was 
1.94 mm (range, 0 to 3.8 mm).  No significant correlations were observed between the measured 
distance and cochlear degeneration. 
 Nerve of origin: There were 11 tumors arising from the vestibular nerve, 11 from the 
superior division of the vestibular nerve and 8 from the inferior division.  There were only 2 
schwannomas arising from the cochlear nerve and they were excluded from this analysis.  There 
were no significant differences between nerve of origin and occurrence of inner hair cell loss, 
outer hair cell loss, strial atrophy and cochlear neuronal loss (t test).  Tumors originating from 
the vestibular nerve showed significantly more hydrops (p=0.002) and more precipitate in the 
endolymph/perilymph (p=0.006) (chi-squared test). 
 
Audiometric Analysis 
 Eight patients had an audiogram recorded within six years of death (mean 2 years, range 1 
month to 6 years).  Figure 4 shows the mean and standard deviation of the air conduction (AC) 
averages at various pure tones for the tumor side compared to the contralateral side.  The AC 
threshold averaged for 0.25, 0.5, 1, 2, 4 and 8 kHz was 70.5 dB on the tumor side and 50.6 dB on 
the contralateral side (a significant difference, p=0.04, t test). 
 Bone conduction (BC) thresholds for frequencies 0.5, 1, 2 and 4 kHz were available in 7 
patients.  The average for these frequencies ranged from 19 dB to 70 dB with a mean of 49 dB 
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for patients with tumors, and from 21 dB to 54 dB with a mean of 35 dB for the non-tumor side.  
The difference was not significant (p = 0.09).   
 Speech discrimination scores were available in 5 patients, ranging from 0 to 96% with a 
mean of 49 % on the tumor side, and a range of 52 to 100% and a mean of 82% for the 
contralateral side.  Due to the small N and the large variance, this rather large difference in the 
mean score between the tumor and the contralateral side was not significant (p=0.15).   
 No significant correlations were observed between tumor volumes and AC thresholds, BC 
thresholds and speech discrimination scores.  Similarly, no significant correlations were noted 
between the distance of the tumor to the cochlea and AC thresholds, BC thresholds and speech 
scores.  Statistical analysis of audiometric data verses nerve of origin was not possible because of 
low number in each group.   
 
DISCUSSION 
 By using the contralateral side as a control (which allows one to eliminate confounding 
variables such as effects of age and genetics in the causation of the observed cochlear 
pathology), we found significantly more inner hair cell loss, outer hair cell loss, cochlear 
neuronal loss and precipitate in the inner ear fluid on the tumor side in the 22 VS cases.  In 
addition, ears with VS showed significantly more hydrops when the analysis was restricted to 
symptomatic tumors. Audiometric data was available in 8 of 22 patients, and significantly 
elevated AC thresholds were observed on the tumor side.  Patients with VS also showed worse 
BC thresholds and speech discrimination scores, but these trends were not significant, probably 
because of small numbers and large variance in the audiometric data.  We also attempted to 
ascertain if cochlear pathology could be correlated to certain morphological aspects of the 
schwannomas.  With a few exceptions, we did not find significant correlations between the 
occurrence of cochlear pathology and tumor volume, distance of tumor to the modiolus and 
nerve of origin of tumor. 
 What might be the mechanisms responsible for the cochlear abnormalities?  Direct invasion 
of the modiolus or the cochlea by schwannoma was not observed in any case, and therefore, is 
unlikely to be a mechanism.  One possibility is vascular compromise (11,15).  We evaluated 
specimens in the MEEI collection and did not find evidence for occlusion of cochlear blood 
vessels on the VS side, nor did we find a decrease in the number of vessels within the cochlea 
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compared to the contralateral side.  These observations notwithstanding, ischemia of the cochlea 
caused by compression of the labyrinthine artery by a VS remains a possible mechanism. 
 Tumors are known to produce a large number of cytokines (31,32) and VS is probably no 
exception.  It has been shown that cytokine balance within the cochlea is critical for its 
homeostasis (33).  It is possible that cytokines produced by a VS might be responsible for 
inducing the observed degenerative changes within the labyrinth.   
 The acidophilic precipitate within the endolymphatic and perilymphatic fluids seen in many 
patients with VS deserves mention.  This abnormality was described in temporal bone specimens 
many decades ago (12,14,16).  Silverstein et al. (34) showed that the perilymph of patients with 
VS has a very high concentration of protein, and it has been assumed that the acidophilic 
precipitate represents such protein.  In fact, before the advent of imaging, high protein 
concentration in a perilymphatic ‘tap’ was used as a diagnostic test to differentiate between 
hearing loss caused by VS verses Meniere’s syndrome (35,36). More recently, proteomic 
analysis of inner ear fluids has shown a higher total protein content in VS patients compared to 
controls (37). 
 The occurrence of cochlear pathology in patients with VS has several implications that are 
of clinical relevance.  It is possible, even likely, that some of the audiometric hearing loss for 
pure tones in patients with VS is caused by cochlear pathology.  A retrocochlear mechanism 
alone cannot explain adequately pure tone losses in many patients with VS, since studies have 
shown that pure tone threshold shifts occur only after losses of over 80-90% of cochlear nerve 
fibers (21).  Speech discrimination is affected disproportionately with atrophy of the cochlear 
nerve (18-20); thus, a purely retrocochlear mechanism of hearing loss would mean that pure tone 
threshold shifts would almost always be accompanied by severe decrement in speech 
discrimination.  Clinical experience has clearly shown that many patients with VS have relative 
preservation of speech discrimination along with pure tone hearing loss (23-27).  Therefore, it is 
logical to conclude that cochlear pathology of the type observed in this study contributes to the 
pure tone threshold shifts in VS.  The lack of correlation between tumor size and hearing loss 
reported in the present study as well as in previous clinical reports (28,29) also suggests that 
neural mechanisms caused by compression of the cochlear nerve are not alone responsible for 
hearing loss in patients with VS. 
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 The occurrence of cochlear pathology has implications regarding the accuracy of 
otoacoustic emissions (OAE) and auditory brain stem response (ABR) testing as diagnostic tools 
for VS. If one assumes that VS affects retrocochlear function and has little effect on the cochlea 
itself (4,5), then VS is expected to result in pathologic ABR with preservation of OAEs.  Clinical 
experience has not borne out this prediction, and it has been observed that OAEs are often absent 
or compromised in VS (11,38,39).  The occurrence of cochlear pathology (e.g. losses of outer 
hair cells) as shown in the present study can explain why emissions may be absent in VS.  
Clinical experience has also shown that a small number of tumors with audiometrically 
documented hearing loss demonstrate a normal ABR (40), an observation that can be explained 
on the basis of a schwannoma causing hearing loss by purely cochlear mechanisms.   
 Sudden loss of hearing is occasionally observed in patients with VS (41-43).  The clinical 
presentation is similar to that seen in the syndrome of idiopathic, sudden sensorineural hearing 
loss.  Furthermore, clinical experience has also shown that sudden hearing loss in VS is usually 
quite responsive to steroid therapy (44,45).  The mechanism of sudden deafness in a patient with 
a VS is not known, and there have been no temporal bone case reports (to our knowledge) where 
a patient with VS had sudden deafness during life.  On theoretical grounds, it is difficult to 
conceive of a retrocochlear mechanism of hearing loss that would be sudden in onset and 
responsive to steroids.  On the other hand, a VS could induce biochemical changes in the cochlea 
which might result in sudden deafness, and which might also be reversed by steroid therapy.  We 
hypothesize that cochlear pathology is responsible for the sudden deafness type of presentation 
seen in a small number of patients with VS.   
 The occurrence of cochlear pathology has implications for hearing outcomes after treatment 
of VS.  Clinical experience has shown that it is rare for a pure tone hearing loss to recover after 
complete surgical removal of a VS, but it is possible to preserve hearing at the preoperative level 
(46,47).  If the hearing loss were caused by a retrocochlear mechanism, one might expect that 
tumor removal could result in hearing improvement in at least some cases.  On the other hand, 
cochlear pathology such as loss of hair cells or strial atrophy (induced by VS) is unlikely to 
reverse, which may explain why successful tumor removal does not result in hearing 
improvement.   
 Treatment of VS with stereotactic radiation or gamma knife radiosurgery often results in 
cessation of further growth of the tumor.  Studies that have assessed long-term hearing outcomes 
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have shown that there is a deterioration of hearing in a small number of patients, at a rate greater 
than that expected for age (48).  The reason(s) for such hearing deterioration is not known.  One 
explanation may be continued progression of cochlear pathology of the type observed in our 
study.  Such progression of pathology may be caused by continued production of cytokines by 
the tumor causing interference with cochlear homeostasis, or continued ischemic compromise of 
the vascular supply to the cochlea, or by other (unknown) mechanisms.  Continued progression 
of cochlear pathology may also be one of the reasons why hearing preservation is often 
unsuccessful when the internal auditory canal is simply decompressed or when a VS is partially 
removed (49). 
 With the advent of molecular biology, targeted therapies are being increasingly developed 
for treatment of VS.  For example, avastin and other drugs have been shown to be beneficial in 
patients with neurofibromatosis type 2 (50,51), and efforts are ongoing to develop similar 
therapies for patients with sporadic VS (52).  The ultimate goals of such targeted therapy are 
cessation of tumor growth and preservation of hearing function.  In order to achieve both goals, it 
will be important to not only stop VS growth, but also to counteract degenerative changes in the 
cochlea of the type that we observed in our study.  Research is needed to understand the 
mechanisms by which VS induce cochlear pathology to ensure that these new molecular 
therapies achieve their promise. 
 
CONCLUSIONS 
 There is significant degeneration of cochlear structures in ears with VS. Cochlear 
dysfunction may be an important contributor to the hearing loss caused by a VS, and can explain 
certain clinically observed phenomena in patients with VS.  
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FIGURES 
 
Figure 1.   
 100-year old woman (Case B5 in Table 1) with untreated solitary vestibular schwannoma 
(VS) approximately 11x8x8 cm in size located at the entrance of the internal auditory canal 
(IAC) in the left temporal bone.  The VS was located mainly in the cerebellopontine angle and 
did not come close to the cochlea in any section. 
 
Figure 2.  
 Same case as Fig. 1.  Photomicrographs of cochlea on VS side are shown along with similar 
views from the contralateral ear.  The low power views demonstrate loss of neuronal cells within 
the modiolus on the VS side (A) compared to the opposite ear (B).  High power views of boxed 
areas show that the organ of Corti in the basal turn was missing (C), while it was preserved on 
the contralateral side (D). The hair cell and neuronal losses were likely to have been caused by 
the VS. 
 
Figure 3.  
 Views of the distal part of the internal auditory canal (IAC), saccule and cochlea from a 75-
year old man (Case B4 in Table 1).  (A) shows a VS in the IAC that reached the fundus but did 
not invade the inner ear.  The cochlea showed acidophilic precipitate within both the 
endolymphatic and perilymphatic spaces (*) as well as endolymphatic hydrops in all turns.  
There was also hydrops of the saccule.  (B) shows comparable view from the contralateral ear 
showing lack of hydrops and lack of precipitate within inner ear fluids.  Higher power views of 
boxed areas are shown in (C) and (D): there was hair cell loss on the VS side (C), with an intact 
organ of Corti in the opposite ear (D).   
 
Figure 4. 
 Comparison of pure tone average for air conduction (AC) thresholds for the tumor side and 
the contralateral side. Standard deviation is indicated by error bars. 
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Table 1  Details of Cochlear Pathology in IAC Schwannomas 
Precipitate  
Case 
sex/ 
Age Side 
Nerve of 
Origin IHC OHC Stria Neurons Hydrops EL PL 
B1 M / 81 Tumor SV  + ++ ++ + - + + 
  contralateral   - - + - - - - 
B2  M / 84 Tumor SV + + ++ + - - - 
  contralateral  - - + - -   
B3 M / 74 Tumor IV + ++ + +++ - - + 
  contralateral  not available 
B4  M / 75 Tumor VN ++ +++ ++ +++ + + + 
  contralateral   + + ++ - - -  
B5 F / 100 Tumor VN ++ ++ ++ +++ - - - 
  contralateral   - - + ++ - - - 
B6 F / 74 Tumor IV + + - - - - - 
  contralateral  + + - - - - - 
B7 M / 79 Tumor SV - - - + - - - 
  contralateral   not available 
B8  M / 80 Tumor IV - - + - - - - 
  contralateral   - - - - - - - 
B9 F / 75 Tumor IV - - + + - - - 
  contralateral   - - + + - - - 
B10 M / 80 Tumor SV - + ++ + - - + 
   contralateral  not available 
B11 F / 81 Tumor SV +++ +++ + + + - - 
   contralateral  not available 
B12  F / 74 Tumor VN +++ +++ - + + + + 
  contralateral   +++ +++ - - + - - 
Z1 M / 25 Tumor VN + ++ - ++ + + + 
   contralateral   + + + + - + + 
Z2 M / 87 Tumor VN +++ ++ ++ ++ - - - 
   contralateral   not available 
Z3 F / 57 Tumor SV - + - + - - - 
   contralateral   not available 
Z4 F / 53 Tumor VN + + - ++ - - + 
   contralateral   not available 
Z5 F / 72 Tumor VN + ++ ++ + - + + 
   contralateral   not available 
Z6 F / 39 Tumor VN ++ ++ - ++ - + + 
   contralateral   - + - + - - + 
M1 M / 72 Tumor VN +++ +++ - + - - - 
   contralateral   not available 
M2 M / 77 Tumor SV + ++ + + - - - 
   contralateral   + ++ + + - - - 
M3 M / 86 Tumor Co +++ +++ +++ +++ + + + 
   contralateral   + + - - - - + 
M4 M / 68 Tumor SV +++ +++ + + - - - 
   contralateral   +++ +++ + + + - - 
M5 M / 81 Tumor SV ++ ++ - +++ - + + 
   contralateral   not available 
M6 M / 67 Tumor SV ++ +++ + ++ - - - 
   contralateral   ++ +++ + + - - - 
M7 M / 76 Tumor VN + +++ - ++ + + + 
   contralateral   + + + ++ - - - 
M8 M / 52 tumor Co - + + + - - - 
   contralateral   - + + + - - - 
M9 M / 44 tumor VN + + + - - + + 
   contralateral   - + + - - - - 
H1 F / 69 tumor IV +++ +++ ++ + - - + 
   contralateral   - + - - - - - 
H2 F / 79 tumor SV - + ++ + - - - 
   contralateral   - + ++ + + - - 
    H3 F / 76 tumor IV + ++ + + - - - 
   contralateral   - - + - - - - 
H4 F / 71 tumor IV - - + - - - - 
   contralateral   - - + - - - - 
H5 F / 94 tumor IV + +++ ++ - + - - 
   contralateral   + ++ + - - - - 
 
IHC=inner hair cells, OHC=outer hair cells, Stria=strial atrophy, Neurons=cochlear neurons, EL=endolymph, PL=perilymph, IV=inferior 
division of vestibular nerve, SV=superior division of vestibular nerve, VN=vestibular nerve, Co=cochlear nerve. 
 
Rating scale for IHC, OHC, Stria, and Neurons: +++ = 67 – 100% loss, ++ = 34 – 66% loss, + = 1 – 33% loss, - = 0% loss 
 
For hydrops and precipitate: + indicates presence, - indicates absence 
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Table 2 
Summary of Cochlear Pathology in IAC Schwannomas in  
22 unilateral VS cases with available contralateral ears 
 
Pathology in 
cochlea 
Severity of 
Change 
Tumor Side 
(n) 
Contralateral Side 
(n) 
none (-) 5 12 
mild (+)  9 7 
moderate (++) 4 1 
IHC Loss 
severe (+++) 4 2 
 
none (-) 3 7 
mild (+)  5 10 
moderate (++) 6 2 
OHC Loss 
severe (+++) 8 3 
 
none (-) 5 6 
mild (+)  9 14 
moderate (++) 7 2 
Strial Atrophy 
severe (+++) 1 0 
 
none (-) 5 12 
mild (+)  10 8 
moderate (++) 4 2 
Cochlear 
Neuronal 
Loss 
severe (+++) 3 0 
 
no 16 19 Hydrops 
yes 6 3 
 
no 14 21 Precipitate in 
Endolymph yes 8 1 
 
no 13 19 Precipitate in 
Perilymph yes 9 3 
 
IHC=inner hair cell, OHC=outer hair cell 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
 
